Semaglutide weight loss: the trial data

Online communities are full of personal semaglutide stories: a year on the drug, 60 or 70 pounds lost, a changed relationship with food. Those accounts are worth reading as signals, but they are individual experiences. The clinical trial data tells a more precise story about what long-term treatment does to weight, body composition, and metabolic health.

What the trials show at one and two years

The STEP 1 trial (Wilding et al., 2021) randomised 1,961 adults with obesity or overweight to semaglutide 2.4 mg weekly or placebo for 68 weeks. The semaglutide group lost a mean 14.9% of body weight, compared with 2.4% on placebo. About 86% of the semaglutide group lost at least 5% of body weight; roughly half lost 15% or more^[1]. Those are averages. Individual responses ranged widely, and the trial enrolled a specific population (BMI of 30 or above, or 27 with at least one weight-related condition, without diabetes).

STEP 5 (Garvey et al., 2022) extended the observation to 104 weeks on the same dose. Mean weight loss was 15.2% with semaglutide versus 2.6% with placebo at two years, and 77.1% of the semaglutide group had lost at least 5% from baseline^[2]. The weight curve largely plateaued between weeks 60 and 68 and then held steady through week 104, suggesting that the drug sustains the loss rather than producing continuous further reduction after the first year.

What happens to body composition

A common concern, both in online forums and in clinical practice, is whether GLP-1 receptor agonist weight loss comes disproportionately from muscle. A 2026 systematic review and meta-analysis by Sawicka-Gutaj et al. pooled body composition data across GLP-1 RA trials. The finding: fat mass decline predominated, with reductions in lean body mass described as modest. The authors characterised this as "selective fat mass reduction, with relative preservation of lean tissue"^[3].

Some lean mass loss does occur with any substantial weight reduction, whether from medication, surgery, or calorie restriction. Whether resistance exercise and adequate protein can offset that loss during GLP-1 RA treatment is an active research question. For now, the muscle-wasting fears appear overstated relative to controlled data, but not baseless.

Eating behaviour and the food noise question

Many semaglutide users describe a reduction in "food noise," the constant mental preoccupation with eating that characterises some people's relationship with food. That language comes from patient communities, not from clinical endpoints, but the underlying phenomenon is starting to appear in the research literature. A 2026 systematic review of incretin-based therapies for binge eating (White et al.) found consistent reductions in binge eating behaviours across 12 studies of GLP-1 receptor agonists, reflected by improvements in Binge Eating Scale scores, lower binge frequency, and higher remission rates^[4].

A smaller retrospective study (Richards et al., 2023) looked at 48 patients with moderate to severe binge eating disorder treated with semaglutide. Patients on semaglutide alone showed greater reductions in binge eating scores than those on combination therapy with other anti-obesity medications^[5]. The authors noted that semaglutide's effects on binge eating disorder warrant further investigation, and that it could offer a safer alternative to some currently approved options that carry abuse potential.

These findings are preliminary. No large randomised trial has tested semaglutide specifically for binge eating disorder. People recovering from eating disorders should work closely with their treatment team before starting any weight-loss medication.

What happens when you stop

The STEP 1 trial extension (Wilding et al., 2022) followed 327 participants for one year after treatment ended. The semaglutide group regained roughly two-thirds of the weight they had lost. At week 120 (one year off drug), their net weight loss from baseline was only 5.6%, down from about 17% at the end of active treatment. Cardiometabolic improvements observed during treatment, including blood pressure and C-reactive protein, reverted towards baseline^[6].

Semaglutide treats obesity the way a blood pressure medication treats hypertension: the benefit persists while you take it, and the condition tends to return when you stop. That framing matters when reading community stories about sustained results, because long-term success stories typically involve continued use, not discontinuation.

Cardiovascular outcomes beyond weight

The SELECT trial (Lincoff et al., 2023) enrolled 17,604 patients with obesity or overweight and established cardiovascular disease (but without diabetes) and followed them for a mean of 39.8 months. Semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (cardiovascular death, nonfatal heart attack, or nonfatal stroke) by 20% compared with placebo (hazard ratio 0.80)^[7]. This was the first trial to show a cardiovascular benefit for a weight-loss medication in patients without diabetes.

SELECT reframes semaglutide from a weight-loss drug to a cardiometabolic treatment. The clinical question extends beyond the scale: does the treatment change hard outcomes? In at least one high-risk population, yes.

Community stories vs. clinical averages

A 68-pound loss over a year is striking but well within the STEP programme range. Reddit threads select for dramatic outcomes. The clinical trials capture the full distribution: non-responders, people who discontinued for side effects (about 7% in STEP 1 for GI reasons), and those whose weight plateaued earlier than expected.

That is not a criticism of personal accounts. A body-fat reduction of 11 percentage points alongside meaningful weight loss is a real result for that person. The useful framing is: community experiences are data points, not the dataset. The semaglutide clinical profile page covers the full trial evidence, and the regulation pages explain how the drug is classified in each country we track.

What we still do not know

Whether weight loss is durable beyond five years of continuous use. Whether body composition shifts over very long treatment. How to predict strong versus modest responders. Whether the binge eating signal holds up in larger trials. And what the best discontinuation strategy looks like. These are open questions.

If you are considering semaglutide for weight management, this article is not a substitute for a conversation with a clinician who knows your history.